Rice Hall James & Associates’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.66M Sell
79,416
-16,170
-17% -$780K 0.19% 114
2026
Q2
$5.61M Sell
95,586
-11,079
-10% -$465K 0.27% 91
2026
Q1
$3.44M Sell
106,665
-1,477
-1% -$54.7K 0.19% 116
2025
Q4
$4.55M Sell
108,142
-19,117
-15% -$771K 0.25% 89
2025
Q3
$4.37M Sell
127,259
-1,034
-0.8% -$29.7K 0.24% 97
2025
Q2
$3.47M Buy
128,293
+12,835
+11% +$372K 0.19% 124
2025
Q1
$3.42M Buy
115,458
+19,843
+21% +$756K 0.2% 112
2024
Q4
$3.79M Sell
95,615
-31,575
-25% -$1.2M 0.21% 112
2024
Q3
$4.33M Buy
+127,190
New +$3.58M 0.23% 97

Other funds holding VCYT

Rice Hall James & Associates's VCYT Position: Q3 2026 in Review

Rice Hall James & Associates reduced its Veracyte (VCYT) stake by 17% in Q3 2026, selling an estimated $780K and leaving 79,416 shares worth $3.66M. The position accounts for 0.19% of the portfolio, ranked #114.

Rice Hall James & Associates first reported a position in VCYT in Q3 2024 and has held it in 9 quarters since. The position peaked at $5.61M in Q2 2026. 383 funds tracked by Wall St. Rank hold VCYT as of Q3 2026.

  • Rice Hall James & Associates held 79,416 shares of Veracyte worth $3.66M as of Q3 2026.
  • Rice Hall James & Associates sold 16,170 Veracyte shares in Q3 2026, an estimated $780K.
  • Veracyte made up 0.19% of Rice Hall James & Associates's portfolio in Q3 2026, its #114 holding.
  • Rice Hall James & Associates first reported a position in Veracyte in Q3 2024 and has held it in 9 quarters since.
  • Rice Hall James & Associates's Veracyte position peaked at $5.61M in Q2 2026.
  • 383 funds tracked by Wall St. Rank held Veracyte as of Q3 2026.

Based on Rice Hall James & Associates's 13F filing for Q3 2026, filed 16 Nov 2026.